Search

Your search keyword '"Mogensen, U"' showing total 39 results
Start Over Author "Mogensen, U"
39 results on '"Mogensen, U"'

2. Risk of lead explantation after first-time implantation of cardiac implantable electronic device as a function of comorbidity: a nationwide study

Author

Alhakak, A, primary, Philbert, B T, additional, Risum, N, additional, Mogensen, U M, additional, Jons, C, additional, Jacobsen, P K, additional, Haarbo, J, additional, Johansen, J B, additional, Nielsen, J C, additional, Riahi, S, additional, Torp-Pedersen, C, additional, Fosbol, E L, additional, Kober, L, additional, Vinther, M, additional, and Weeke, P E, additional

Published
2022
Full Text
View/download PDF

3. Incidence of thyroid dysfunction following initiation of amiodarone treatment in patients with and without heart failure: a nationwide cohort study

Author

Ali, S A A, primary, Ersboll, M E, additional, Vinding, N J V, additional, Butt, J H B, additional, Rorth, R R, additional, Selmer, C S, additional, Westergaard, L M W, additional, Mogensen, U M M, additional, Weeke, P E W, additional, Jons, C J, additional, Gustafsson, F G, additional, Fosbol, E F, additional, Kober, L K, additional, and Kristensen, S L K, additional

Published
2022
Full Text
View/download PDF

4. Risk of lead explantation after first-time implantation of cardiac implantable electronic device as a function of comorbidity: a nationwide study

Author

Alhakak, A., Philbert, B. T., Risum, N., Mogensen, U. M., Jons, C., Jacobsen, P. K., Haarbo, J., Johansen, J. B., Nielsen, J. C., Riahi, S., Torp-Pedersen, C., Fosbol, E. L., Kober, L., Vinther, M., and Weeke, P. E.

Subjects
Cardiology and Cardiovascular Medicine
Abstract

Background The benefit of cardiac implantable electronic devices (CIEDs) is challenged by the risk of procedure-related complications and lead explantation. Whether patient comorbidity burden is associated with risk of lead explantation Purpose We assessed the risk of lead explantation and its association with comorbidity burden within 6 months after first-time CIED implantation. Methods The study population comprised patients ≥18 years old with first-time CIED implantation (i.e., pacemaker [PM], implantable cardioverter defibrillator [ICD], and cardiac resynchronisation therapy with defibrillator [CRT-D] or without [CRT-P]) using Danish nationwide registries including the Danish Pacemaker and ICD registry (1 January 2000 to 30 June 2018). Patients were followed from their first-time CIED implantation and 6 months forward. Patient comorbidity burden was categorised in four groups according to the Charlson Comorbidity Index (CCI) score: 0 (none), 1–2 (mild), 3–4 (moderate), and ≥5 (severe). Multivariable cause-specific Cox regression was performed to assess risk of lead explantation according to comorbidity burden, with death as competing risk. Comorbidity burden was adjusted for sex, age, type of CIED, and body mass index categories. Results We identified 73,491 patients with first-time CIED implantation including 55,733 (75.8%) with PM, 11,351 (15.5%) with ICD, 2,989 (4.1%) with CRT-P, and 3,418 (4.7%) with CRT-D. In total, 1,049 (1.4%) patients underwent lead explantation. The median age of the study population was 75.1 years [25th-75th percentile 66.2–82.5 years], and 62.1% were male. Patients undergoing lead explantation had higher median CCI score, compared with those not undergoing lead explantation (2 [1–3] and 1 [0–3], respectively). The median age and distribution of sex were similar in both groups. In the multivariable Cox regression model (Figure 1), an increase in patient comorbidity burden was associated with higher hazard ratio [HR] of lead explantation, compared with CCI score 0 (CCI score 1–2: HR=1.38 [95% confidence interval [CI]: 1.12–1.69], CCI score 3–4: HR=1.61 [95% CI: 1.28–2.03], and CCI score ≥5: HR=1.60 [95% CI: 1.25–2.05]). Conclusion Risk of lead explantation within 6 months after first-time implantation of cardiac implantable electronic device was 1.4% and associated with higher comorbidity burden. Funding Acknowledgement Type of funding sources: Foundation. Main funding source(s): Independent Research Fund Denmark

Published
2022

15. P3411Health-related quality of life is associated with all-cause mortality in patients with non-ischemic heart failure: results of the DANISH trial

Author

Bundgaard, J, primary, Fosboel, E L, additional, Jensen, G, additional, Aagaard, D, additional, Videbaek, L, additional, Gislason, G, additional, Torp-Pedersen, C, additional, Nielsen, J C, additional, Haarbo, J, additional, Thoegersen, A M, additional, Koeber, L, additional, and Mogensen, U, additional

Published
2018
Full Text
View/download PDF

16. P2490The impact of ICD implantation on health-related quality of life in the DANISH trial

Author

Bundgaard, J, primary, Pehrson, S, additional, Nielsen, J C, additional, Videbaek, L, additional, Haarbo, J, additional, Bruun, N E, additional, Svendsen, J H, additional, Thune, J J, additional, Brandes, A, additional, Egstrup, K, additional, Thoegersen, A M, additional, Eiskjaer, H, additional, Korup, E, additional, Koeber, L, additional, and Mogensen, U M, additional

Published
2018
Full Text
View/download PDF

29. Poster session II * Thursday 9 December 2010, 14:00-18:00

Author

Pabari, P. A., primary, Kyriacou, A., additional, Moraldo, M., additional, Unsworth, B., additional, Baruah, R., additional, Sutaria, N., additional, Hughes, A., additional, Mayet, J., additional, Francis, D. P., additional, Uejima, T., additional, Loboz, K., additional, Antonini-Canterin, F., additional, Polombo, C., additional, Carerj, S., additional, Vinereanu, D., additional, Evangelista, A., additional, Leftheriotis, G., additional, Fraser, A. G., additional, Kiotsekoglou, A., additional, Govindan, M., additional, Govind, S. C., additional, Saha, S. K., additional, Camm, A. J., additional, Azcarate, P. M., additional, Castano, S., additional, Rodriguez-Manero, M., additional, Arraiza, M., additional, Levy, B., additional, Barba, J., additional, Rabago, G., additional, Bastarrika, G., additional, Nemes, A., additional, Takacs, R., additional, Varkonyi, T., additional, Gavaller, H., additional, Baczko, I., additional, Forster, T., additional, Wittmann, T., additional, Papp, J. G., additional, Lengyel, C., additional, Varro, A., additional, Tumasyan, L. R., additional, Adamyan, K. G., additional, Savu, O., additional, Mieghem, T., additional, Dekoninck, P., additional, Gucciardo, L., additional, Jurcut, R., additional, Giusca, S., additional, Popescu, B. A., additional, Ginghina, C., additional, Deprest, J., additional, Voigt, J. U., additional, Versiero, M., additional, Galderisi, M., additional, Esposito, R., additional, Rapacciuolo, A., additional, Esposito, G., additional, Raia, R., additional, Morgillo, T., additional, Piscione, F., additional, De Simone, G., additional, Oraby, M. A., additional, Maklady, F. A., additional, Mohamed, E. M., additional, Eraki, A. Z., additional, Zaliaduonyte-Peksiene, D., additional, Tamuleviciute, E., additional, Janenaite, J., additional, Marcinkeviciene, J., additional, Mizariene, V., additional, Bucyte, S., additional, Vaskelyte, J., additional, Trifunovic, D., additional, Nedeljkovic, I., additional, Popovic, D., additional, Ostojic, M., additional, Vujisic-Tesic, B., additional, Petrovic, M., additional, Stankovic, S., additional, Sobic-Saranovic, D., additional, Banovic, M., additional, Dikic-Djordjevic, A., additional, Savino, K., additional, Lilli, A., additional, Grikstaite, E., additional, Giglio, V., additional, Bordoni, E., additional, Maragoni, G., additional, Cavallini, C., additional, Ambrosio, G., additional, Jakovljevic, B., additional, Beleslin, B., additional, Nedeljkovic, M., additional, Petrovic, O., additional, Moral, S., additional, Rodriguez-Palomares, J., additional, Descalzo, M., additional, Marti, G., additional, Pineda, V., additional, Mahia, P., additional, Gutierrez, L., additional, Gonzalez-Alujas, T., additional, Garcia-Dorado, D., additional, Schnell, F., additional, Donal, E., additional, Thebault, C., additional, Bernard, A., additional, Corbineau, H., additional, Le Breton, H., additional, Kochanowski, J., additional, Scislo, P., additional, Piatkowski, R., additional, Roik, M., additional, Marchel, M., additional, Kosior, D., additional, Opolski, G., additional, Lesniak-Sobelga, A. M., additional, Wicher-Muniak, E., additional, Kostkiewicz, M., additional, Olszowska, M., additional, Suchon, E., additional, Klimeczek, P., additional, Banys, P., additional, Pasowicz, M., additional, Tracz, W., additional, Podolec, P., additional, Laynez, A., additional, Hoefsten, D. E., additional, Loegstrup, B. B., additional, Norager, B., additional, Moller, J. E., additional, Flyvbjerg, A., additional, Egstrup, K., additional, Streb, W., additional, Szulik, M., additional, Nowak, J., additional, Markowicz-Pawlus, E., additional, Duszanska, A., additional, Sedkowska, A., additional, Kalarus, Z., additional, Kukulski, T., additional, Spinelli, L., additional, Morisco, C., additional, Assante Di Panzillo, E., additional, Buono, F., additional, Crispo, S., additional, Trimarco, B., additional, Hawary, A. A., additional, Nasr, G. M., additional, Fawzy, M. M., additional, Faber, L., additional, Scholtz, W., additional, Boergermann, J., additional, Wiemer, M., additional, Kleikamp, G., additional, Bogunovic, N., additional, Dimitriadis, Z., additional, Gummert, J., additional, Hering, D., additional, Horstkotte, D., additional, Luca', F., additional, Gelsomino, S., additional, Lorusso, R., additional, Caciolli, S., additional, Carella, R., additional, Bille', G., additional, De Cicco, G., additional, Pazzagli, V., additional, Gensini, G. F., additional, Borowiec, A., additional, Dabrowski, R., additional, Janas, J., additional, Kraska, A., additional, Firek, B., additional, Kowalik, I., additional, Szwed, H., additional, Marcus, K. A., additional, De Korte, C. L., additional, Feuth, T., additional, Thijssen, J. M., additional, Kapusta, L., additional, Dahl, J., additional, Videbaek, L., additional, Poulsen, M. K., additional, Pellikka, P. A., additional, Veien, K., additional, Andersen, L. I., additional, Haghfelt, T., additional, Haberka, M., additional, Mizia - Stec, K., additional, Adamczyk, T., additional, Mizia, M., additional, Chmiel, A., additional, Pysz, P., additional, Sosnowski, M., additional, Gasior, Z., additional, Trusz - Gluza, M., additional, Tendera, M., additional, Niklewski, T., additional, Wilczek, K., additional, Chodor, P., additional, Podolecki, T., additional, Frycz-Kurek, A., additional, Zembala, M., additional, Yurdakul, S., additional, Yildirimturk, O., additional, Tayyareci, Y., additional, Memic, K., additional, Demiroglu, I. C. C., additional, Aytekin, S., additional, Garcia Alonso, C. J., additional, Ferrer Sistach, E., additional, Delgado, L., additional, Lopez Ayerbe, J., additional, Vallejo Camazon, N., additional, Gual Capllonch, F., additional, Espriu Simon, M., additional, Ruyra, X., additional, Caballero Parrilla, A., additional, Bayes Genis, A., additional, Lecuyer, L., additional, Berrebi, A., additional, Florens, E., additional, Noghin, M., additional, Huerre, C., additional, Achouh, P., additional, Zegdi, R., additional, Fabiani, J. N., additional, De Chiara, B., additional, Moreo, A., additional, Musca, F., additional, De Marco, F., additional, Lobiati, E., additional, Belli, O., additional, Mauri, F., additional, Klugmann, S., additional, Caballero, A., additional, Vallejo, N., additional, Gonzalez Guardia, A., additional, Nunez Aragon, R., additional, Bosch, C., additional, Ferrer, E., additional, Pedro Botet, M. L., additional, Gual, F., additional, Cusma-Piccione, M., additional, Zito, C., additional, Oreto, G., additional, Giuffre, R., additional, Todaro, M. C., additional, Barbaro, C. M., additional, Lanteri, S., additional, Longordo, C., additional, Salvia, J., additional, Bensaid, A., additional, Gallet, R., additional, Fougeres, E., additional, Lim, P., additional, Nahum, J., additional, Deux, J. F., additional, Gueret, P., additional, Teiger, E., additional, Dubois-Rande, J. L., additional, Monin, J. L., additional, Behramoglu, F., additional, Colakoglu, Z., additional, Aytekin, V., additional, Demiroglu, C., additional, Gargani, L., additional, Poggianti, E., additional, Bucalo, R., additional, Rizzo, M., additional, Agrusta, F., additional, Landi, P., additional, Sicari, R., additional, Picano, E., additional, Sutandar, A., additional, Siswanto, B. B., additional, Irmalita, I., additional, Harimurti, G., additional, Hayashi, S. Y., additional, Nascimento, M. M., additional, Lindholm, B., additional, Lind, B., additional, Seeberger, A., additional, Pachaly, M. A., additional, Riella, M. C., additional, Bjallmark, A., additional, Brodin, L. A., additional, Poanta, L., additional, Porojan, M., additional, Dumitrascu, D. L., additional, Ikonomidis, I., additional, Tzortzis, S., additional, Lekakis, J., additional, Kremastinos, D. T., additional, Paraskevaidis, I., additional, Andreadou, I., additional, Nikolaou, M., additional, Katsibri, P., additional, Anastasiou-Nana, M., additional, Maceira Gonzalez, A. M., additional, Ripoll, C., additional, Cosin-Sales, J., additional, Igual, B., additional, Salazar, J., additional, Belloch, V., additional, Cosin-Aguilar, J., additional, Pennell, D. J., additional, Masaki, M., additional, Pulido, J. N., additional, Yuasa, T., additional, Gillespie, S., additional, Afessa, B., additional, Brown, D. R., additional, Mankad, S. V., additional, Oh, J. K., additional, Gurghean, A. L., additional, Mihailescu, A. M., additional, Tudor, I., additional, Homentcovschi, C., additional, Muraru, M., additional, Bruckner, I. V., additional, Correia, C. E., additional, Rodrigues, B., additional, Moreira, D., additional, Santos, L. F., additional, Gama, P., additional, Dionisio, O., additional, Cabral, C., additional, Santos, O., additional, Bombardini, T., additional, Gherardi, S., additional, Arpesella, G., additional, Valente, S., additional, Calamai, I., additional, Pasanisi, E., additional, Sansoni, S., additional, Szymanski, P., additional, Dobrowolski, P., additional, Lipczynska, M., additional, Klisiewicz, A., additional, Hoffman, P., additional, Stepowski, D., additional, Kurtz, B., additional, Grezis-Soulie, G., additional, Savoure, A., additional, Anselme, F., additional, Bauer, F., additional, Castillo, J., additional, Herszkowicz, N., additional, Ferreira, C., additional, Goscinska, A., additional, Mizia-Stec, K., additional, Poborski, W., additional, Azevedo, O., additional, Quelhas, I., additional, Guardado, J., additional, Fernandes, M., additional, Miranda, C. S., additional, Gaspar, P., additional, Lourenco, A., additional, Medeiros, R., additional, Almeida, J., additional, L Bennani, S., additional, Algalarrondo, V., additional, Dinanian, S., additional, Guiader, J., additional, Juin, C., additional, Adams, D., additional, Slama, M. S., additional, Onaindia, J. J., additional, Quintana, O., additional, Velasco, S., additional, Astigarraga, E., additional, Cacicedo, A., additional, Gonzalez, J., additional, Rodriguez, I., additional, Sadaba, M., additional, Eneriz, M., additional, Laraudogoitia Zaldumbide, E., additional, Nunez-Gil, I., additional, Luaces, M., additional, Zamorano, J., additional, Garcia Rubira, J. C., additional, Vivas, D., additional, Ibanez, B., additional, Marcos Alberca, P., additional, Fernandez Golfin, C., additional, Alonso, J., additional, Macaya, C., additional, Silva Marques, J., additional, Almeida, A. G., additional, Carvalho, V., additional, Jorge, C., additional, Silva, D., additional, Gato Varela, M., additional, Martins, S., additional, Brito, D., additional, Lopes, M. G., additional, Tripodi, E., additional, Miserrafiti, B., additional, Montemurro, V., additional, Scali, R., additional, Tripodi, P., additional, Winkler, A., additional, Madej, A., additional, Hausmanowa-Petrusewicz, I., additional, Fijalkowski, M., additional, Koprowski, A., additional, Jaguszewski, M., additional, Galaska, R., additional, Taszner, M., additional, Rynkiewicz, A., additional, Citro, R., additional, Rigo, F., additional, Provenza, G., additional, Ciampi, Q., additional, Patella, M. M., additional, D'andrea, A., additional, Vriz, O., additional, Astarita, C., additional, Bossone, E., additional, Heggemann, F., additional, Walter, T. H., additional, Kaelsch, T. H., additional, Sueselbeck, T., additional, Papavassiliu, T. H., additional, Borggrefe, M., additional, Haghi, D., additional, Monk-Hansen, T., additional, Have Dall, C., additional, Bisgaard Christensen, S., additional, Snoer, M., additional, Gustafsson, F., additional, Rasmusen, H., additional, Prescott, E., additional, Finocchiaro, G., additional, Pinamonti, B., additional, Merlo, M., additional, Barbati, G., additional, Di Lenarda, A., additional, Bussani, R., additional, Sinagra, G., additional, Butz, T., additional, Lang, C. N., additional, Meissner, A., additional, Plehn, G., additional, Yeni, H., additional, Langer, C., additional, Trappe, H. J., additional, Gu, X., additional, Gu, X. Y., additional, He, Y. H., additional, Li, Z. A., additional, Han, J. C., additional, Chen, J., additional, Gaudron, P., additional, Niemann, M., additional, Herrmann, S., additional, Hu, K., additional, Bijnens, B., additional, Hillenbrand, H., additional, Beer, M., additional, Ertl, G., additional, Weidemann, F., additional, Mazzone, A., additional, Mariani, M., additional, Foffa, I., additional, Vianello, A., additional, Del Ry, S., additional, Bevilacqua, S., additional, Andreassi, M. G., additional, Glauber, M., additional, Berti, S., additional, Grabowski, M., additional, Postula, M., additional, Dragulescu, A., additional, Van Arsdell, G., additional, Al-Radi, O., additional, Caldarone, C., additional, Mertens, L., additional, Lee, K. J., additional, Casula, R. P., additional, Yadav, H., additional, Cherian, A., additional, Hughes, A. D., additional, Vitarelli, A., additional, D'orazio, S., additional, Nguyen, B. L., additional, Iorio, G., additional, Battaglia, D., additional, Caranci, F., additional, Padella, V., additional, Capotosto, L., additional, Alessandroni, L., additional, Barilla, F., additional, Cardin, C., additional, Hascoet, S., additional, Saudron, M., additional, Caudron, G., additional, Arnaudis, B., additional, Acar, P., additional, Sun, M. M., additional, Shu, X. H., additional, Pan, C. Z., additional, Fang, X. Y., additional, Kong, D. H., additional, Fang, F., additional, Zhang, Q., additional, Chan, Y. S., additional, Xie, J. M., additional, Yip, W. K., additional, Lam, Y. Y., additional, Sanderson, J. E., additional, Yu, C. M., additional, Rosca, M., additional, O' Connor, K., additional, Romano, G., additional, Magne, J., additional, Calin, A., additional, Muraru, D., additional, Pierard, L., additional, Lancellotti, P., additional, Roushdy, A., additional, Elfiky, I., additional, El Shahid, G., additional, Elfiky, A., additional, El Sayed, M., additional, Wierzbowska-Drabik, K., additional, Chrzanowski, L., additional, Kapusta, A., additional, Plonska-Goscinak, E., additional, Krzeminska-Pakula, M., additional, Kurpesa, M., additional, Rechcinski, T., additional, Trzos, E., additional, Kasprzak, J. D., additional, Ersboll, M. K., additional, Valeur, N., additional, Mogensen, U. M., additional, Andersen, M., additional, Hassager, C., additional, Sogaard, P., additional, Kober, L. V., additional, Kloeckner, M., additional, Hayat, D., additional, Dussault, C., additional, Lellouche, N., additional, Elbaz, N., additional, Demopoulos, A., additional, Hatzigeorgiou, G., additional, Leontiades, E., additional, Motsi, A., additional, Karatasakis, G., additional, Athanassopoulos, G., additional, Zycinski, P., additional, Kasprzak, J., additional, Vazquez Alvarez, M. C., additional, Medrano Lopez, C., additional, Camino Lopez, M., additional, Granja, S., additional, Zunzunegui Martinez, J. L., additional, Maroto Alvaro, E., additional, Tsai, W.-C., additional, Chen, J.-Y., additional, Liu, Y.-W., additional, Lin, C.-C., additional, Tsai, L.-M., additional, Gomes, D. C., additional, Robalo Martins, S., additional, Gois, M. R., additional, Ribeiro, S., additional, Nunes Diogo, A., additional, Sengupta, P., additional, Di Bella, G., additional, Caracciolo, G., additional, Lentini, S., additional, Kinova, E., additional, Zlatareva, N., additional, Goudev, A., additional, Papagiannis, N., additional, Mpouki, M., additional, Papagianni, A., additional, Vorria, M., additional, Mpenetos, G., additional, Lytra, D., additional, Papadopoulou, E., additional, Sgourakis, P., additional, Malakos, J., additional, Kyriazis, J., additional, Kodali, V., additional, Toole, R., additional, Gopal, A. S., additional, Celutkiene, J., additional, Rudys, A., additional, Grabauskiene, V., additional, Glaveckaite, S., additional, Sadauskiene, E., additional, Lileikiene, Z., additional, Bickauskaite, N., additional, Ciburiene, E., additional, Skorniakov, V., additional, Laucevicius, A., additional, Attenhofer Jost, C. H., additional, Pfyffer, M., additional, Lindquist, R., additional, Santos, J. L. F., additional, Coelho, O. R. C., additional, Mady, C. M., additional, Picard, M. H. P., additional, Salemi, V. M. C., additional, Funk, L., additional, Prull, M. W., additional, Shih, J.-Y., additional, Huang, Y.-Y., additional, O'connor, K., additional, Moonen, M., additional, Pierard, L. A., additional, Cozma, D. C., additional, Mornos, C., additional, Ionac, A., additional, Petrescu, L., additional, Dragulescu, D., additional, Dan, R., additional, Popescu, I., additional, Dragulescu, S. I., additional, Von Lueder, T. G., additional, Hodt, A., additional, Gjerdalen, G. F., additional, Andersen, T. E., additional, Solberg, E. E., additional, Steine, K., additional, Van Mieghem, T., additional, Rostek, M., additional, Pikto-Pietkiewicz, W., additional, Dluzniewski, M., additional, Antoniewicz, A., additional, Poletajew, S., additional, Borowka, A., additional, Pasierski, T., additional, Malyutina, S. K., additional, Ryabikov, M., additional, Ragino, J., additional, Ryabikov, A., additional, Sitia, S., additional, Tomasoni, L., additional, Atzeni, F., additional, Gianturco, L., additional, Sarzi-Puttini, P., additional, De Gennaro Colonna, V., additional, Turiel, M., additional, Gutierrez, F. R., additional, Lefhtheriotis, G., additional, Hurst, R. T., additional, Nelson, M. R., additional, Mookadam, F., additional, Thota, V., additional, Emani, U., additional, Al Harthi, M., additional, Stepanek, J., additional, Cha, S., additional, Lester, S. J., additional, Ho, E. M. M., additional, Hemeryck, L., additional, Hall, M., additional, Scott, K., additional, Bennett, K., additional, Mahmud, A., additional, Daly, C., additional, King, G., additional, Murphy, R. T., additional, Brown, A. S., additional, Teske, A. J., additional, D'Hooge, J., additional, Claus, P., additional, Rademakers, F., additional, Santos, L., additional, Cortez-Dias, N., additional, Goncalves, S., additional, Almeida Ribeiro, M., additional, Bordalo E Sa, A., additional, Magnino, C., additional, Marcos-Alberca, P., additional, Milan, A., additional, Almeria, C., additional, Caniadas, V., additional, Rodrigo, J. L., additional, Perez De Isla, L., additional, Zamorano, J. L., additional, Gustafsson, U., additional, Larsson, M., additional, Lindqvist, P., additional, Brodin, L., additional, Waldenstrom, A., additional, Roosens, B., additional, Hernot, S., additional, Droogmans, S., additional, Van Camp, G., additional, Lahoutte, T., additional, Cosyns, B., additional, Rao, C. M., additional, Aguglia, D., additional, Casciola, G., additional, Imbesi, C., additional, Marvelli, A., additional, Sgro, M., additional, Benedetto, D., additional, Tripepi, R., additional, Zoccali, C., additional, Benedetto, F. A., additional, Badano, L. P., additional, Cardillo, M., additional, Del Mestre, L., additional, Gianfagna, P., additional, Proclemer, A., additional, Tschernich, H. D., additional, Mora, B., additional, Base, E., additional, Weber, U., additional, Dumfarth, J., additional, Mukherjee, C., additional, Skaltsiotis, H. S., additional, Kaladaridis, A. K., additional, Bramos, D. B., additional, Kottis, G. K., additional, Antoniou, A. A., additional, Agrios, I. A., additional, Takos, D. T., additional, Vasiladiotis, N. V., additional, Pamboucas, K. P., additional, Toumanidis, S. T. T., additional, Shim, A., additional, Lipec, P., additional, Michalski, B., additional, Wozniakowski, B., additional, Stefanczyk, L., additional, Rotkiewicz, A., additional, Cameli, M., additional, Lisi, M., additional, Padeletti, M., additional, Bigio, E., additional, Bernazzali, S., additional, Tsoulpas, C., additional, Maccherini, M., additional, Henein, M., additional, Mondillo, S., additional, Garcia Lunar, I., additional, Mingo Santos, S., additional, Monivas Palomero, V., additional, Mitroi, C., additional, Beltran Correas, P., additional, Ruiz Bautista, L., additional, Muniz Lozano, A., additional, Gonzalez Gonzalez, M., additional, Pabari, P. A., additional, Stegemann, B., additional, Willson, K., additional, Zeppellini, R., additional, Iavernaro, A., additional, Zadro, M., additional, Carasi, M., additional, De Domenico, R., additional, Rigo, T., additional, Artuso, E., additional, Erente, G., additional, Ramondo, A., additional, Le, T. T., additional, Huang, F. Q., additional, Gu, Y., additional, and Tan, R. S., additional

Published
2010
Full Text
View/download PDF

31. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF

Author

Mogensen, Ulrik M., Køber, Lars, Jhund, Pardeep S., Desai, Akshay S., Senni, Michele, Kristensen, Søren L., Dukát, Andrej, Chen, Chen-Huan, Ramires, Felix, Lefkowitz, Martin P., Prescott, Margaret F., Shi, Victor C., Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Packer, Milton, McMurray, John J.V., Mogensen, U, Køber, L, Jhund, P, Desai, A, Senni, M, Kristensen, S, Dukát, A, Chen, C, Ramires, F, Lefkowitz, M, Prescott, M, Shi, V, Rouleau, J, Solomon, S, Swedberg, K, Packer, M, and Mcmurray, J

Subjects
Male, Tetrazoles, Heart failure, Angiotensin Receptor Antagonists, Angiotensin, Double-Blind Method, Humans, Mortality, Heart Failure, Aminobutyrates, Biphenyl Compounds, Stroke Volume, Focus on Clinical Trials, Middle Aged, Prognosis, Uric Acid, Drug Combinations, Treatment Outcome, Valsartan, Female, Neprilysin, Co‐morbidities in Clinical Trials, Uric acid, Biomarkers, Follow-Up Studies, Glomerular Filtration Rate, Research Article
Abstract

Aims Elevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders. We examined the association between SUA and outcomes as well as the effect of sacubitril/valsartan on SUA in patients with heart failure with reduced ejection fraction (HFrEF) in PARADIGM-HF. ..................................................................................................................................................................... Methods and results The association between SUA and the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization, its components, and all-cause mortality was examined using Cox regression analyses among 8213 patients using quintiles (Q1–Q5) of SUA adjusted for baseline prognostic variables including estimated glomerular filtration rate (eGFR), diuretic dose, and log N-terminal pro-brain natriuretic peptide. Change in SUA from baseline over 12 months was also evaluated in each treatment group. Patients in Q5 (SUA ≥8.6 mg/dL) compared with Q1 ( < 5.4 mg/dL) were younger (62.8 vs. 64.2 years), more often male (88.7% vs. 63.1%), had lower systolic blood pressure (119 vs. 123 mmHg), lower eGFR (57.4 vs. 76.6 mL/min/1.73 m2), and greater diuretic use. Higher SUA was associated with a higher risk of the primary outcome (adjusted hazard ratios) Q5 vs. Q1=1.28 [95% confidence intervals (1.09–1.50), P =0.003], cardiovascular death [1.44 (1.11–1.77), P =0.001], HF hospitalization [1.37 (1.11–1.70), P =0.004], and all-cause mortality [1.36 (1.13–1.64), P =0.001]. Compared with enalapril, sacubitril/valsartan reduced SUA by 0.24 (0.17–0.32) mg/dL over 12 months (P < 0.0001). Sacubitril/valsartan improved outcomes, irrespective of SUA concentration. ..................................................................................................................................................................... Conclusion Serum uric acid concentration was an independent predictor of worse outcomes after multivariable adjustment in patients with HFrEF. Compared with enalapril, sacubitril/valsartan reduced SUA and improved outcomes irrespective of SUA.

Published
2018

32. Healthcare cost variation in patients with heart failure: a nationwide study.

Author

Bundgaard JS, Mogensen UM, Christensen S, Ploug U, Rørth R, Ibsen R, Kjellberg J, and Køber L

Subjects
Female, Health Care Costs, Humans, Longitudinal Studies, Male, Retrospective Studies, Heart Failure therapy, Hospitalization
Abstract

Objective: Heart failure (HF) imposes a major economic burden; however, the individual management for patients varies, potentially leading to large cost heterogeneity. The aim of this study was to investigate the spectrum of health cost by patients with HF and factors associated with high direct health cost., Study Design: This was a nationwide, retrospective longitudinal study., Methods: Using Danish nationwide registries from 2012 to 2015, we identified all patients aged >18 years with a first-time diagnosis of HF. Total health costs were investigated using two perspectives-at index and during 3 years of follow-up. Patients were investigated by decile cost groups. A multivariable logistic regression was used to identify variables associated with being in the highest cost decile compared with the rest (90%)., Results: A total of 11,170 patients with HF were included, and those in the highest cost decile (n = 1117, 10%) were younger (69 vs. 75 years), fewer were females (34% vs. 43%), and more were inpatients (83% vs. 70%) compared with the rest of the patients with HF (n = 10,053, 90%). Patients in the highest cost decile (10%) incurred a 30 times higher cost with a mean total health cost in index year of €86,607 compared with €2893 for patients in lowest cost decile (10%). The results were similar for 3 years aggregated (€139,473 vs. €4086), corresponding to a 34 times higher cost., Conclusion: In patients with HF, a large total health cost heterogeneity exists with younger age, inpatient admittance, male sex, and comorbidities being associated with a higher likelihood of belonging to the highest cost group., (Copyright © 2022 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.)

Published
2022
Full Text
View/download PDF

33. Is hidradenitis suppurativa associated with anaemia?: a population-based and hospital-based cross-sectional study from Denmark.

Author

Miller IM, Johansen ME, Mogensen UB, Zarchi K, Ellervik C, and Jemec GB

Subjects
Adult, Case-Control Studies, Cross-Sectional Studies, Denmark, Female, Humans, Male, Middle Aged, Young Adult, Anemia complications, Hidradenitis Suppurativa complications
Abstract

Background: Chronic inflammatory diseases may be associated with anaemia of inflammation. Hidradenitis suppurativa is a chronic inflammatory dermatological disease associated with metabolic comorbidities, low quality of life and fatigue. Anaemia may cause fatigue, and it has been hypothesized that HS-related fatigue may be partly due to anaemia., Objective: Our objective was to investigate a possible association between HS and anaemia., Methods: We performed a hospital-based and population-based cross-sectional study investigating the red blood cell profile, i.e. haemoglobin., Results: We identified a total of 32 hospital HS individuals, 430 population HS individuals and 20,780 population non-HS control individuals. The age-sex-smoking-adjusted analyses showed no differences in the haemoglobin level of the HS groups vs. the control group. Analyses of the anaemic subgroup of HS individuals revealed that 60% had normocytic anaemia and 40% microcytic anaemia, in concordance with anaemia of inflammation., Conclusion: In contrast to our hypothesis, this study showed that HS is not associated with anaemia. Thus, anaemia may not be the cause of the described fatigue in HS patients. Furthermore, the results indicate that if an HS patient does suffer from anaemia it is most likely to be normocytic or microcytic and thus compatible with anaemia seen in other chronic inflammatory disorders., (© 2015 European Academy of Dermatology and Venereology.)

Published
2016
Full Text
View/download PDF

34. Body composition and basal metabolic rate in Hidradenitis Suppurativa: a Danish population-based and hospital-based cross-sectional study.

Author

Miller IM, Rytgaard H, Mogensen UB, Miller E, Ring HC, Ellervik C, and Jemec GB

Subjects
Adult, Cross-Sectional Studies, Denmark, Female, Hidradenitis Suppurativa physiopathology, Humans, Male, Middle Aged, Young Adult, Body Composition, Hidradenitis Suppurativa metabolism
Abstract

Background: Several studies have suggested an association between Hidradenitis Suppurativa (HS) and obesity. Obesity is often expressed as Body Mass Index (BMI). However, BMI lacks information on body composition. General obesity is a predictor of health status and cardiovascular risk, but body composition (e.g. abdominal fat) may be more so. Basal metabolic rate (BMR) is an expression of resting metabolism and may serve as a complementary tool when assessing the possibly underlying metabolism behind a persons' body composition., Objective: To investigate the body composition and basal metabolic rate in individuals with HS compared with healthy controls., Methods: We performed a cross-sectional study on both a hospital-based and population-based HS group and compared with controls using Bioelectrical Impedance Analysis to assess body composition., Results: We identified a hospital-based HS group of 32 hospital HS patients, a population-based HS group of 430 population HS patients, and 20 780 controls. Age- and sex-adjusted analyses showed a 10.12% (P < 0.0001) significantly higher fat percentage in the hospital-based HS group and 3.11% (P < 0.0001) significantly higher fat percentage for the population-based HS group compared to controls. Correspondingly, the HS groups had a lower muscle percentage (P < 0.0001) and lower bone mass percentage (P < 0.0001). Furthermore, visceral fat rating (P < 0.0001), Body Mass Index (P < 0.0001), waist circumference (P < 0.0001), and Waist/Hip Ratio (P < 0.0001) was significantly higher in HS patients compared with controls. Additionally, age and sex-adjusted analyses showed a higher predicted estimate of BMR for the HS groups compared with controls (154.56 kcal/day (95% CI 54.96-254.16) (P = 0.0031) for the hospital-based HS group, and 82.63 kcal/day (95%CI 59.70-105.56) (P < 0.0001) for the population-based HS group)., Conclusion: Hidradenitis Suppurativa is associated with a high fat percentage, high visceral fat, and low muscle percentage adding to the morbidity of HS. The higher predicted estimate of basal metabolic rate (BMR) in HS patients may reflect a dysfunctional metabolism contributing to the high-fat-body composition., (© 2015 European Academy of Dermatology and Venereology.)

Published
2016
Full Text
View/download PDF

35. Hidradenitis suppurativa may not be associated with venous thromboembolia: Results from a large Danish cross-sectional study.

Author

Miller IM, Ahlehoff O, Ibler K, Rytgaard H, Mogensen UB, Ellervik C, and Jemec GB

Subjects
Adult, Aged, Aged, 80 and over, Case-Control Studies, Cross-Sectional Studies, Denmark epidemiology, Female, Humans, Male, Middle Aged, Pulmonary Embolism epidemiology, Pulmonary Embolism etiology, Risk Factors, Venous Thromboembolism epidemiology, Young Adult, Hidradenitis Suppurativa complications, Venous Thromboembolism etiology
Published
2016
Full Text
View/download PDF

36. Myocardial perfusion at rest in patients with Diabetes Mellitus Type 1 compared with healthy controls assessed with Multi Detector Computed Tomography.

Author

Byrne C, Jensen T, Hjortkjær HØ, Mogensen UM, Kuhl JT, Fuchs A, Hilsted J, Nordestgaard BG, Køber L, and Kofoed KF

Subjects
Adult, Aged, Case-Control Studies, Female, Humans, Male, Middle Aged, Myocardial Ischemia metabolism, Risk Factors, Tomography, X-Ray Computed methods, Diabetes Mellitus, Type 1 physiopathology, Myocardial Ischemia physiopathology
Abstract

Aim: Type 1 diabetes mellitus (T1DM) is associated with an increased risk of ischemic heart disease (IHD). The relative contribution of structural and functional abnormalities of the coronary circulation determining clinically manifested IHD remains unknown. The aim of this study was to assess potential differences in myocardial perfusion at rest and coronary atherosclerosis between asymptomatic T1DM patients and healthy controls., Methods: Left ventricular (LV) myocardial perfusion at rest measured as LV myocardial Attenuation Density/LV blood pool Attenuation Density (MyoAD-ratio) and coronary artery atherosclerosis were evaluated with 320-multidetector computed tomography angiography in 57 asymptomatic T1DM patients and 114 sex and age matched controls., Results: In both groups median age was 53 years (p5,p95: 42,67) and 59.6% were men. Median duration of diabetes in the T1DM group was 35 years (p5,p95: 17,49). Median coronary calcium score was higher in T1DM patients (51 vs. 2, p=0.037) compared with controls. However, a similar frequency of >50% stenosis in one or more coronary arteries was found in T1DM patients and controls (18% vs. 14%, p=0.49). LV myocardial perfusion at rest (MyoAD-ratio) was 18% higher in T1DM patients than controls (0.13 vs. 0.11, p<0.0001). This difference was noted throughout all the LV myocardial segments. In a multiple regression analysis including diabetes, sex, age, cardiovascular risk factors, heart rate, calcium score and coronary stenosis >50%, MyoAD-ratio remained significantly higher in T1DM patients (p=0.0001)., Conclusions: LV myocardial perfusion at rest is higher in T1DM patients compared with controls independent of coronary atherosclerosis and cardiovascular risk factors., (Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.)

Published
2015
Full Text
View/download PDF

37. Nocturnal antihypertensive treatment in patients with type 1 diabetes with autonomic neuropathy and non-dipping of blood pressure during night time: protocol for a randomised, placebo-controlled, double-blind, two-way crossover study.

Author

Hjortkær H, Jensen T, Kofoed K, Mogensen U, Køber L, Hilsted KL, Corinth H, Theilade S, and Hilsted J

Subjects
Adult, Aged, Blood Pressure, Blood Pressure Monitoring, Ambulatory, Cross-Over Studies, Double-Blind Method, Drug Chronotherapy, Female, Humans, Hypertension etiology, Hypertrophy, Left Ventricular diagnostic imaging, Male, Middle Aged, Multidetector Computed Tomography, Organ Size, Young Adult, Antihypertensive Agents administration & dosage, Autonomic Nervous System Diseases complications, Diabetes Mellitus, Type 1 complications, Diabetic Neuropathies complications, Enalapril administration & dosage, Heart Ventricles diagnostic imaging, Hypertension drug therapy
Abstract

Introduction: Cardiac autonomic neuropathy (CAN) and elevated nocturnal blood pressure are independent risk factors for cardiovascular disease in patients with diabetes. Previously, associations between CAN, non-dipping of nocturnal blood pressure and coronary artery calcification have been demonstrated. The present protocol describes a trial to test the efficacy of bedtime dosing of the ACE inhibitor enalapril on night time blood pressure and left ventricular mass in patients with type 1 diabetes., Materials and Methods: In a randomised, double-blind, two-way cross-over study, 24 normoalbuminuric patients with type 1 diabetes with CAN will be treated for 12 weeks with either morning or bedtime dosing of 20 mg enalapril, followed by 12 weeks of switched treatment regimen. During each treatment period, two 24 h ambulatory blood pressure measurements will be performed and after each treatment period left ventricular mass will be determined by multisliced CT. Primary end points will be reduction in blood pressure and reduction in left ventricular mass., Ethics and Dissemination: The study has been approved by the Danish Medicines Agency, the Scientific-Ethical Committee of the Capital Region of Denmark and the Danish Data Protection Agency. An external monitoring committee (the Good Clinical Practice Unit at Copenhagen University Hospital) will oversee the study. The results of the study will be presented at national and international scientific meetings and publications will be submitted to peer-reviewed journals., Trial Registration Number: EudraCT (2012- 002136-90)., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.)

Published
2014
Full Text
View/download PDF

38. Normal tension glaucoma and Alzheimer disease: comorbidity?

Author

Bach-Holm D, Kessing SV, Mogensen U, Forman JL, Andersen PK, and Kessing LV

Subjects
Aged, Aged, 80 and over, Alzheimer Disease diagnosis, Antihypertensive Agents therapeutic use, Ciliary Body surgery, Comorbidity, Denmark epidemiology, Female, Humans, Intraocular Pressure, Laser Coagulation, Low Tension Glaucoma diagnosis, Low Tension Glaucoma therapy, Male, Middle Aged, Registries, Risk Factors, Trabeculectomy, Alzheimer Disease epidemiology, Low Tension Glaucoma epidemiology
Abstract

Purpose: To investigate whether normal tension glaucoma (NTG) is associated with increased risk of developing dementia/Alzheimer disease (AD)., Methods: A total of 69 patients with NTG were identified in the case note files in the Glaucoma Clinic, University Hospital of Copenhagen (Rigshospitalet), Denmark from 1980 to 2001. The rate of a subsequent diagnosis of dementia as recorded in nationwide health care registers from 1980 to 2005 was estimated and compared with the rate for the general population [standard mortality rate (SMR) = observed number of cases of dementia/expected number of cases of dementia]., Results: The 69 patients had a median age of 64 years (quartiles 57 and 73) at the time of the diagnosis, and the average follow-up period was 12.7 years. The SMR(dementia) was 0.20 (95% CI 0.01-1.11). No patient developed AD., Conclusion: Normal tension glaucoma was not associated with an increased risk of developing dementia/AD., (© 2011 The Authors. Acta Ophthalmologica © 2011 Acta Ophthalmologica Scandinavica Foundation.)

Published
2012
Full Text
View/download PDF

39. Venous thromboembolism in pregnant and puerperal women in Denmark 1995-2005. A national cohort study.

Author

Virkus RA, Løkkegaard EC, Bergholt T, Mogensen U, Langhoff-Roos J, and Lidegaard Ø

Subjects
Adolescent, Adult, Cohort Studies, Denmark epidemiology, Female, Humans, Middle Aged, Pregnancy, Pregnancy Trimesters, Registries, Risk Factors, Young Adult, Pregnancy Complications, Cardiovascular epidemiology, Puerperal Disorders epidemiology, Venous Thromboembolism complications, Venous Thromboembolism epidemiology
Abstract

Venous thromboembolism (VTE) is the leading cause of maternal death in the Western world, and the risk increases during pregnancy and puerperal period. It was the objective of the present study to estimate the absolute and the relative risk of VTE at different weeks of gestation and in the postnatal period as compared to non-pregnant women. This was a historical controlled national cohort study. The National Registry of Patients identified relevant diagnoses. These data were linked to The National Registry of Medical Products Statistics for information about current use of oral contraceptives. Danish women 15 to 49 years old during the period January 1995 through December 2005 were included in the study. In total 819,751 pregnant women were identified of whom 727 had a diagnosis of VTE. The absolute risk of VTE per 10,000 pregnancy-years increased from 4.1 (95% CI, 3.2 to 5.2) during week 1-11 up to 59.0 (95% CI: 46.1 to 76.4) in week 40 and decreased in the puerperal period from 60.0 (95% CI:47.2-76.4) during the first week after birth to 2.1 (95% CI:1.1 to 4.2) during week 9-12 after birth. Compared with non-pregnant women, the incidence rate ratio rose from 1.5 (95% CI:1.1 to 1.9) in week 1-11, to 21.0 (95%CI16.7 to 27.4) in week 40 and 21.5 (95% CI:16.8 to 27.6) in the first week after delivery, declining to 3.8 (95% CI:2.5 to 5.8) 5-6 weeks after delivery. In conclusion, the risk of VTE increases almost exponentially through pregnancy and reaches maximum just after delivery and is no longer significantly increased six weeks after delivery.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results